Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy

Human Gene Therapy

Volumn 23, Issue 9, 2012, Pages 951-959

  Oneal, Michael J ^a   Trujillo, Miguel A ^a   Davydova, Julia ^b   McDonough, Samantha ^a   Yamamoto, Masato ^b   Morris, John C ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CONDITIONALLY REPLICATING ADENOVIRUS; IODINE 131; SODIUM IODIDE SYMPORTER; VIRUS PROTEIN;

ADENOVIRUS; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL STRAIN LNCAP; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS HYBRID; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84866332629     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.047     Document Type: Article

References (42)

1. Andriani, F., Nan, B., Yu, J., et al. (2001). Use of the probasin promoter ARR2PB to express Bax in androgen receptorpositive prostate cancer cells. J. Natl. Cancer Inst. 93, 1314-1324. (Pubitemid 32910572)
2. Barton, K.N., Paielli, D., Zhang, Y., et al. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 13, 347-356. (Pubitemid 43056900)
3. Barton, K.N., Stricker, H., Brown, S.L., et al. (2008). Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol. Ther. 16, 1761-1769.
4. Cho, J.-Y., Xing, S., Liu, X., et al. (2000). Expression and activity of human Na +I-symporter in human glioma cells by adenovirus mediated gene therapy. Gene Ther. 7, 740-749. (Pubitemid 30255755)
5. Crnalic, S., Hö rnberg, E., Wikström, P., et al. (2010). Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr. Relat. Cancer 17, 885-895.
6. Dash, R., Dmitriev, I., Su, Z.Z., et al. (2010). Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther. 17, 447-456.
7. Davis, B.J. (2011 (ongoing)). Gene therapy and radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy. Available at http://clinicaltrials.gov/ct2/ show/NCT00788307 (accessed June 22, 2012).
8. Davydova, J., Le, L.P., Gavrikova, T., et al. (2004). Infectivityenhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res. 64, 4319-4327. (Pubitemid 38802439)
9. Davydova, J., Gavrikova, T., Brown, E.J., et al. (2010). In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci. 101, 474-481.
10. Dingli, D., Peng, K.-W., Harvey, M.E., et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646. (Pubitemid 38268954)
11. Doronin, K., Toth, K., Kuppuswamy, M., et al. (2003). Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387. (Pubitemid 36259672)
12. Dwyer, R.M., Bergert, E.R., O'Connor, M.K., et al. (2005). In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin. Cancer Res. 11, 1483-1489. (Pubitemid 40315230)
13. Edwards, J., Krishna, N.S., Grigor, K.M., and Bartlett, J.M.S. (2003). Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br. J. Cancer 89, 552-556. (Pubitemid 37026442)
14. Galanis, E. (2011 (ongoing)). Recombinant measles virus vaccine therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer. Available at http://clinical trials.gov/ct2/show/NCT00408590 (accessed June 22, 2012).
15. Gregory, C.W., Johnson, R.T., Mohler, J.L., et al. (2001). Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898. (Pubitemid 32691931)
16. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
17. Holzbeierlein, J., Lal, P., Latulippe, E., et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164, 217-227. (Pubitemid 38364606)
18. Hugosson, J., Stranne, J., and Carlsson, S.V. (2011). Radical retropubic prostatectomy: a review of outcomes and side-effects. Acta Oncol. 50, 92-97.
19. Jemal, A., Bray, F., Center, M.M., et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
20. Kakinuma, H., Bergert, E.R., Spitzweg, C., et al. (2003). Probasin promoter (ARR2PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 63, 7840-7844. (Pubitemid 37466717)
21. Kuster, K., Koschel, A., Rohwer, N., et al. (2010). Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1[alpha]. Cancer Gene Ther. 17, 141-146.
22. Linja, M.J., Savinainen, K.J., Saramä ki, O.R., et al. (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555. (Pubitemid 32694958)
23. Luster, M., Clarke, S., Dietlein, M., et al. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1941-1959.
24. Lutz, P., and Kedinger, C. (1996). Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. J. Virol. 70,1396-1405.
25. Mandell, R.B., Mandell, L.Z., and Link, C.J. (1999). Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 59, 661-668. (Pubitemid 29076065)
26. Mottet, N., Bellmunt, J., Bolla, M., et al. (2011). EAU Guidelines on Prostate Cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59, 572-583.
27. Murakami, M., Ugai, H., Belousova, N., et al. (2010). Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells. Prostate 70, 362-376.
28. Ono, H.A., Le, L.P., Davydova, J.G., et al. (2005). Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region. Cancer Res. 65, 10154-10158. (Pubitemid 41743702)
29. Qu, C.F., Li, Y., Song, Y.J., et al. (2004). MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate. Br. J. Cancer 91, 2086-2093. (Pubitemid 40128776)
30. Rauen, K.A., Sudilovsky, D., Le, J.L., et al. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma. Cancer Res. 62, 3812-3818. (Pubitemid 34728866)
31. Scosyrev, E., Messing, E.M., Mohile, S., et al. (2011). Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118, 3062-3070.
32. Spitzweg, C., Dietz, A.B., O'Connor, M.K., et al. (2001). In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8, 1524-1531. (Pubitemid 33061890)
33. Tannock, I.F., De Wit, R., Berry, W.R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512. (Pubitemid 39315317)
34. Tollefson, A.E., Ryerse, J.S., Scaria, A., et al. (1996). The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with ADP mutants. Virology 220, 152-162. (Pubitemid 26201673)
35. Tribouley, C., Lutz, P., Staub, A., and Kedinger, C. (1994). The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter. J. Virol. 68, 4450-4457. (Pubitemid 24183040)
36. Trojan, L., Schaaf, A., Steidler, A., et al. (2005). Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 25, 183-191. (Pubitemid 40470109)
37. Trujillo, M., Oneal, M., Davydova, J., et al. (2009). Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res. 11, R53.
38. Trujillo, M.A., Oneal, M.J., McDonough, S., et al. (2010). A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther. 17, 1325-1332.
39. Waehler, R., Russell, S.J., and Curiel, D.T. (2007). Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573-587. (Pubitemid 47077278)
40. Wang, H., Li, Z.-Y., Liu, Y., et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 17, 96-104.
41. Yamamoto, M., Davydova, J., Wang, M., et al. (2003). Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 125, 1203-1218. (Pubitemid 37193465)
42. Zhang, J., Thomas, T.Z., Kasper, S., and Matusik, R.J. (2000). A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141, 4698-4710. (Pubitemid 32055150)